Real-world examples of two health systems actively using real-world evidence (RWE) to advance their Precision Oncology programs. Examples will be centered around clinical quality and patient care value in the areas of molecular tumor board (MTB) support, clinical trial optimization, and health disparities in BRCA testing.
Dr. Anna Berry i works in partnership with Syapse’s functional leaders to support product and service development, serves as a subject matter expert to Syapse’s customers, participates in joint-authored research and publications, and advances Syapse’s thought leadership efforts in the area of real-world evidence. Prior to her recent move to Syapse, she served for 6 years as the Deputy Director for Molecular Pathology and Genomics, and as the Scientific Director for the Personalized Medicine Program at the Swedish Cancer Institute in Seattle, and concurrently served as Director of Genomics Programs at CellNetix Pathology and Laboratories. Dr. Berry has focused professionally on genomics education and personalized medicine. In these roles, she has given numerous presentations, nationally and internationally, and has served on multiple task forces and committees for several professional organizations and coalitions, spanning Pathology and Oncology focused efforts.
Mary Walters is a clinical pharmacist at Advocate Aurora Health in Milwaukee who serves as a co-director of the Oncology Precision Medicine program, oncology pharmacy practice counsel chair, and Aurora specialty pharmacy oncology specialist. Walters obtained her Bachelor of Arts degree in chemistry with a biochemistry concentration at Saint Catherine University in Saint Paul, Minnesota in 2012 and her Doctor of Pharmacy degree from the University of Minnesota, Twin Cities in 2016. Walters trained as a PGY-1 pharmacy resident at the Level 1 Trauma Center, North Memorial Medical Center, in Robbinsdale, Minnesota where she developed a ketamine pain management protocol and an interest in oncology. For her PGY-2, Walters specialized in oncology at Advocate Aurora, optimizing pharmacy transition of care for patients with cancer. Walters remained at Advocate Aurora and has served as a clinical pharmacist in the Milwaukee metro area cancer clinics and inpatient services for three years.
Dr. Ali’s Clinical and academic interests are in discovering the impact of ethnic disparities in the biology of different neoplastic processes. Dr. Ali became interested in keloid disorder as it is another disorder where ethnicity plays a significant role in the biology and clinical presentation of the disease process. Dr. Ali is an active participant in national and international trials through his active participation with the national cancer institute cooperative group research mechanism and numerous industry-supported clinical trials. He is an active member of both the Southwest Oncology Group (SWOG) and NRG Oncology. He is bringing all his clinical trial expertise to design and conduct trials that we are planning to conduct in the very near future in keloid patients. Dr. Ali is an active member of the American Medical Association, American Society of Clinical Oncology, European society of clinical oncology, and the Michigan Society of Hematology and Oncology.